AD pathology accompanies numerous molecular changes that may coalesce into key signaling components, such as PI3K, STAT, PTEN, and mTOR (Oddo, 2012; Sanabria-Castro et al., 2017; Chen and Mobley, 2019; Yamazaki et al., 2019), which are also downstream players of MET signaling (Peng et al., 2013). The gene discussed is MET; the disease is Alzheimer disease.